Melanoma Clinical Trial
Official title:
Evaluation of Two Different Schedules of Palonosetron for the Prevention of Nausea and Vomiting in Patients With Metastatic Melanoma Receiving Concurrent Biochemotherapy
Primary Objectives:
- Safety of palonosetron administered for control of nausea and vomiting in patients with
metastatic melanoma receiving biochemotherapy.
- To determine the patterns and severity of nausea and vomiting in two groups of patients
with metastatic melanoma receiving biochemotherapy with palonosetron premedication
using two schedules of palonosetron administration.
Palonosetron is designed to work by blocking the substance serotonin from binding to the
brain and gastrointestinal tract, which may help to decrease nausea and vomiting.
Participants in this study will be receiving biochemotherapy treatment as part of their
routine care. This treatment will include 3 chemotherapy drugs (cisplatin, vinblastine, and
DTIC) and 2 drugs that stimulate the immune system (interferon and interleukin-2 (IL-2)).
Biochemotherapy often causes nausea, vomiting, loss of appetite, and weight loss.
Palonosetron will be given on this study to try to treat the side effects of
biochemotherapy.
If you agree to take part in this study, you will be randomly assigned (as in the toss of a
coin) to one of 2 treatment groups. You have an equal chance of being assigned to either
group.
Participants in Group 1 will receive palonosetron by vein over a few minutes starting 30
minutes before receiving chemotherapy on Days 1 and 4 of therapy. Participants in Group 2
will receive palonosetron by vein over a few minutes on Days 1, 3, and 5.
All participants on this study will also receive Ativan by vein every 8 hours for 5 days.
Ativan is given for additional control of nausea and it will also help to sedate you. In
addition to palonosetron, you may be given standard anti-nausea medications such as
lorazepam or compazine if you experience intolerable nausea and vomiting while on study.
You will also be asked to fill out a Functional Living Index-Emesis (FLIE) questionnaire
every day for 7 days in a row. The questionnaire will ask about any nausea and/or vomiting
you are experiencing and the effect of the therapy on your quality of life. You will stay in
the hospital for at least 7 days while you receive treatment.
After the first course of palonosetron given with biochemotherapy, your doctor will decide
if you will receive additional courses of palonosetron or if you will be given another
anti-nausea drug.
If your doctor does decide to have you continue on palonosetron, it will be given off study.
Your participation in this study will be over after 1 course.
This is an investigational study. Palonosetron has been approved by FDA for control of
nausea and vomiting caused by chemotherapy. However, it has not been adequately evaluated
for safety and effectiveness in patients receiving high dose interleukin-2 alone or in
combination with chemotherapy. About 30 patients will take part in this study. All patients
will enrolled at M. D. Anderson.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
| Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
| Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|